Inovio Pharmaceuticals is trading 5.17% down at $1.10, primarily amid biotech-sector weakness, with no new company-specific catalyst surfacing for September 16, 2026.
- Its latest listed corporate update was a September 1 investor-conference announcement.
- The next major catalyst is the FDA’s October 30 decision on INO-3107.
- Biotech fell 2.11% during regular trading while major indexes were mixed to higher, making the move more consistent with biotech risk reduction than broad-market selling.